) Stock-based compensation expenses included in operating expenses
amounted to approximately:
Research and
development $439 $553 $1,565 $2,444
Selling, general
and administrative 851 1,326 2,607 3,859
Restructuring and
impairment charges ----- 968 ----- 968
IDENIX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)
September 30, December 31,
2008 2007
ASSETS
Cash and cash equivalents $45,695 $48,260
Marketable securities 6,935 39,862
Receivables from related party 984 11,196
Other current assets 3,218 4,401
Total current assets 56,832 103,719
Intangible asset, net 12,677 13,548
Property and equipment, net 14,054 15,460
Marketable securities, non-current 7,461 23,882
Other assets 4,337 3,931
Total assets $95,361 $160,540
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses $12,165 $21,809
Deferred revenue, related party 5,764 8,372
Other current liabilities 667 553
Total current liabilities 18,596 30,734
Long-term obligations
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs2.
Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results3.
Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference4.
Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results5.
Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)6.
Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference7.
Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference8.
Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference9.
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results10.
Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference11.
Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results